QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 限定条件 专题：吉林大学白求恩第一医院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 会议论文 作者:  Senkus-Konefka, E.;  Domchek, S. M.;  Im, S. A.;  Xu, B.;  Armstrong, A. 收藏  |  浏览/下载：12/0  |  提交时间：2019/12/05 OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) 期刊论文 Journal of Clinical Oncology, 2017, 卷号: 35 作者:  Robson M.E., Im S.-A., Senkus E., Xu B., Domchek S.M., Masuda N., Delaloge S., Li W., Tung N.M., Armstrong A., Wu W., Goessl C.D., Runswick S., Conte P.F. 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05 OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). 会议论文 作者:  Robson, Mark E.;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe;  Domchek, Susan M. 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/05 OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician"s choice 会议论文 作者:  Runswick, S.;  Robson, M.;  Conte, P. F.;  Im, S-A.;  Senkus-Konefka, E. 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05 OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice (TPC) 期刊论文 ANNALS OF ONCOLOGY, 2017, 卷号: 28 作者:  Robson, M.;  Ruddy, K. J.;  Im, S-A.;  Senkus-Konefka, E.;  Xu, B. 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05